Engineering Xenopus embryos for phenotypic drug discovery screening

Area of Science:

• Developmental Biology
• Genetics
• Pharmacology

Background:

• Many rare human inherited diseases lack effective treatments, even when causative genes and animal models are known.
• In vivo phenotypic drug screening requires models that allow for efficient testing of drug candidates.
• Non-mammalian models are valuable for studying human diseases and discovering therapeutics.

Purpose of the Study:

• To review the application of genome editing tools in Xenopus for modeling human inherited diseases.
• To discuss the advantages of Xenopus embryos as in vivo models for disease research.
• To explore the utility of Xenopus embryos in drug discovery screening.

Main Methods:

• Utilizing novel genome editing tools such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas.
• Engineering Xenopus embryos to create models of human inherited diseases.
• Employing Xenopus embryos in high-throughput in vivo phenotypic drug screening.

Main Results:

• Rapid progress has been made in adapting genome editing tools to Xenopus.
• Xenopus embryos are suitable for in vivo phenotypic drug screening due to their abundance, small size, and ease of manipulation.
• Engineered Xenopus models can effectively study human inherited disease pathologies.

Conclusions:

• Xenopus embryos represent a valuable and complementary non-mammalian model to zebrafish for investigating human inherited diseases.
• Genome-edited Xenopus embryos are highly effective for in vivo drug discovery and the identification of novel therapeutics for untreatable genetic disorders.